Recent Update on PCSK9 and Platelet Activation Experimental Research Methods: In Vitro and In Vivo Studies

Overview

Journal J Cardiovasc Dev Dis

Specialty Cardiology & Vascular Diseases

Date 2022 Aug 25

PMID 36005422

Authors

Meidi Utami Puteri

Nuriza Ulul Azmi

Salbiah Ridwan

Muhammad Iqbal

Tresni Fatimah

Tri Diana Puspita Rini

Mitsuyasu Kato

Fadlina Chany Saputri

Affiliations

Soon will be listed here.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial factor in the development and progression of cardiovascular diseases. PCSK9 has been demonstrated to modify LDL plasma levels and increase platelet activation, which promotes atherosclerosis, a defining feature of nearly all cardiovascular diseases. Platelet activation has been shown to promote and maintain the response to atherosclerosis development, from beginning to progression and exacerbation, which can lead to advanced cardiovascular events including myocardial infarction (MI) or death. Research on PCSK9 and platelet activation is currently underway with the main goal of reducing the risk of advanced cardiovascular events by preventing or slowing down atherosclerosis progression. Both in vitro and in vivo studies have been used to explore PCSK9 functions to develop new drugs targeting PCSK9. Finding the most suitable study models that represent the pathological and physiological systems found in humans is very important to achieving the goal. This review aimed to present a current and comprehensive overview of the experimental models that have been used to investigate the role of PCSK9 in platelet activation-induced atherosclerotic cardiovascular diseases.

Citing Articles

High-Fat Diet Enhances Platelet Activation and Is Associated with Proprotein Convertase Subtilisin Kexin 9: An Animal Study.

Saputri F, Azmi N, Puteri M, Damayanti , Novita V, Marisi G Nutrients. 2023; 15(20).

PMID: 37892538 PMC: 10609754. DOI: 10.3390/nu15204463.

References

Fan J, Kitajima S, Watanabe T, Xu J, Zhang J, Liu E . Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine. Pharmacol Ther. 2014; 146:104-19. PMC: 4304984. DOI: 10.1016/j.pharmthera.2014.09.009. View

Andreadou I, Tsoumani M, Vilahur G, Ikonomidis I, Badimon L, Varga Z . PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation. Front Physiol. 2020; 11:602497. PMC: 7688516. DOI: 10.3389/fphys.2020.602497. View

Horton J, Cohen J, Hobbs H . Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007; 32(2):71-7. PMC: 2711871. DOI: 10.1016/j.tibs.2006.12.008. View

Puteri M, Azmi N, Kato M, Saputri F . PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction. Life (Basel). 2022; 12(2). PMC: 8875594. DOI: 10.3390/life12020190. View

Silverstein R, Febbraio M . CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009; 2(72):re3. PMC: 2811062. DOI: 10.1126/scisignal.272re3. View

Wang J, Bo H, Meng X, Wu Y, Bao Y, Li Y . A simple and fast experimental model of myocardial infarction in the mouse. Tex Heart Inst J. 2006; 33(3):290-3. PMC: 1592260. View

Yuan F, Guo L, Park K, Woollard J, Taek-Geun K, Jiang K . Ossabaw Pigs With a PCSK9 Gain-of-Function Mutation Develop Accelerated Coronary Atherosclerotic Lesions: A Novel Model for Preclinical Studies. J Am Heart Assoc. 2018; 7(6). PMC: 5907533. DOI: 10.1161/JAHA.117.006207. View

Cameron J, Holla O, Ranheim T, Kulseth M, Berge K, Leren T . Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet. 2006; 15(9):1551-8. DOI: 10.1093/hmg/ddl077. View

Camera M, Rossetti L, Barbieri S, Zanotti I, Canciani B, Trabattoni D . PCSK9 as a Positive Modulator of Platelet Activation. J Am Coll Cardiol. 2018; 71(8):952-954. DOI: 10.1016/j.jacc.2017.11.069. View

10.

Elseweidy M, Amin R, Atteia H, El-Zeiky R, Al-Gabri N . New Insight on a Combination of Policosanol and 10-Dehydrogingerdione Phytochemicals as Inhibitors for Platelet Activation Biomarkers and Atherogenicity Risk in Dyslipidemic Rabbits: Role of CETP and PCSK9 Inhibition. Appl Biochem Biotechnol. 2018; 186(4):805-815. DOI: 10.1007/s12010-018-2776-5. View

11.

Badimon L, Padro T, Vilahur G . Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care. 2013; 1(1):60-74. PMC: 3760546. DOI: 10.1177/2048872612441582. View

12.

Petersen-Uribe A, Kremser M, Rohlfing A, Castor T, Kolb K, Dicenta V . Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease. Int J Mol Sci. 2021; 22(20). PMC: 8538687. DOI: 10.3390/ijms222011179. View

13.

Musunuru K, Chadwick A, Mizoguchi T, Garcia S, DeNizio J, Reiss C . In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021; 593(7859):429-434. DOI: 10.1038/s41586-021-03534-y. View

14.

Al-Mashhadi R, Sorensen C, Kragh P, Christoffersen C, Mortensen M, Tolbod L . Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. Sci Transl Med. 2013; 5(166):166ra1. DOI: 10.1126/scitranslmed.3004853. View

15.

El-Seweidy M, Amin R, Atteia H, El-Zeiky R, Al-Gabri N . Dyslipidemia induced inflammatory status, platelet activation and endothelial dysfunction in rabbits: Protective role of 10-Dehydrogingerdione. Biomed Pharmacother. 2018; 110:456-464. DOI: 10.1016/j.biopha.2018.11.140. View

16.

Seidah N, Awan Z, Chretien M, Mbikay M . PCSK9: a key modulator of cardiovascular health. Circ Res. 2014; 114(6):1022-36. DOI: 10.1161/CIRCRESAHA.114.301621. View

17.

Dwivedi D, Grin P, Khan M, Prat A, Zhou J, Fox-Robichaud A . Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis. Shock. 2016; 46(6):672-680. DOI: 10.1097/SHK.0000000000000682. View

18.

Barale C, Bonomo K, Frascaroli C, Morotti A, Guerrasio A, Cavalot F . Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutr Metab Cardiovasc Dis. 2019; 30(2):282-291. DOI: 10.1016/j.numecd.2019.09.012. View

19.

Wang L, Breton C, Warzecha C, Bell P, Yan H, He Z . Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9. Mol Ther. 2021; 29(6):2019-2029. PMC: 8178442. DOI: 10.1016/j.ymthe.2021.02.020. View

20.

Qi Z, Hu L, Zhang J, Yang W, Liu X, Jia D . PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36. Circulation. 2020; 143(1):45-61. DOI: 10.1161/CIRCULATIONAHA.120.046290. View